# [PAX5]

## Mutation tier

|Entity|Tier|
|------|----|
|DLBCL |2   |

## Mutation incidence

|Entity|study         |frequency (%)|
|------|--------------|-------------|
|DLBCL |GAMBL genomes |4.5          |
|DLBCL |Schmitz cohort|3.2          |
|DLBCL |Reddy cohort  |1.9          |
|DLBCL |Chapuy cohort |3.4          |

## Mutation pattern

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|------|----|---------------------|----------------|----------------|
|BL    |Yes |No                   | 6.750          |0               |
|DLBCL |Yes |Yes                  |14.089          |0               |
|FL    |Yes |No                   |10.963          |0               |

## aSHM regions

|chr_name|hg19_start|hg19_end|region           |regulatory_comment|
|--------|----------|--------|-----------------|------------------|
|chr9    |37023396  |37027663|intron-1         |intron            |
|chr9    |37029849  |37037154|TSS-1            |active_promoter   |
|chr9    |37369209  |37372160|distal-enhancer-1|enhancer          |
|chr9    |37382267  |37385854|distal-enhancer-2|enhancer          |
|chr9    |37395932  |37409239|distal-enhancer-3|enhancer          |

> [!NOTE]
> First described in DLBCL in 2001 by [Pasqualucci L](https://pubmed.ncbi.nlm.nih.gov/11460166)